Skip to main content
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
Next-Generation Proteasome Inhibition in Multiple Myeloma
Supplements
Kim Redic
PharmD, BCPS
Beth Faiman, PhD, APRN-BC, AOCN
Founding Editor in Chief
Download PDF
Supported by funding from Onyx Pharmaceuticals, Inc.
*This publication is not sponsored by, endorsed by, or affiliated with the American Society of Hematology in any way.
Articles
Advances in the Treatment of Multiple Myeloma: Next-Generation Proteasome Inhibition
The Emerging Role of Carfilzomib in Multiple Myeloma
Carfilzomib: A New Agent in the Treatment Armamentarium for Multiple Myeloma
Related Items
Staying Abreast of New Treatments
By
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH Highlights
Survivorship Care and Multiple Myeloma
By
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH Highlights
How Janssen CarePath Helps Patients
By
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH Highlights
Concerns Over New Multiple Myeloma Therapies
By
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH Highlights